The Significance Evaluation of Adverse Effect of Doxorubicin 50mg/m2 – cyclophosphamide 500mg/m2 Versus Docetaxel 60mg/m2 on Minangnese Operable Breast Cancer Chemotherapy – A Retrospective Single Institution
Description
Patient Characteristic Between January and December of 2022, 146 patients underwent AC-T chemotherapy at the Dr. M. Djamil General Hospital, and 125 patient samples (85.6%) were diagnosed as over 40 years old. adverse effect of AC-T The following adverse effects of administering doxorubicin-cyclophosphamide are listed in order of severity were anorexia, which was reported by 106 patients, or roughly 72.4%; epithelial toxicity, or stomatitis, was reported by 109 patients, or roughly 74.6%; and alopecia, which was reported by 103 patients, or roughly 70.5%. Neurocognitive disorder ranks next in terms of adverse effects, with up to 97 individuals (or around 66.4%) reporting cognitive impairment. The following most common adverse effect was shown to be hematological toxicity, based on laboratory findings, fifty-two patients, or 35.6%, the ANC (Absolute Neutrophil Count) levels found in lower numbers, and sixty-six patients, or 54.7% of the patient population, had hemoglobin values that were considered anemia. When administered the doxorubicin-cyclophosphamide agent, patients reported chest pain in as many as 37 cases or 25.3%, and palpitations in as many as 48 cases (32.8%). the comparison of AC-T adverse effect Significant differences in adverse effects were observed in five of twelve toxicities. The administration of AC's (Doxorubicin 50mg/m2 – Cyclophosphamide 500mg/m2) resulted in a notable rise in chest pain which has a p-value = 0.000, palpitation has a p-value = 0.008, behavioral changes has a p–value = 0.008, and neutropenia has a p-value = 0.001, which are adverse consequences. However, the adverse effect of T (Docetaxel 60mg/m2) notably led to an increased occurrence of alopecia, p-value = 0.041.